So if one finds a cure and can save a good portion of the $5 billion in hospital cost for survivors would one spend $600,000,000 on treatment? Works out to about $1,000 per patient. This is an old report and deals with E5 not Neuprex when XOMA is discussed. Decided not to spend the $900 until the report is revised. <g>
Free Summary Page
View the description or purchase the publication
THE U.S. MARKET FOR SEPSIS THERAPEUTICS
AND PREVENTIVE AGENTS
Market Size and
Growth
The first products to prevent or treat sepsis or septic shock are expected in 1998, and the
U.S. market could reach $300 million that year in current manufacturers' dollars. By the
year 2000, the U.S. sepsis product market may achieve sales of $600 million.
Definition
The presentation of systemic inflammatory response syndrome (SIRS) ranges from
sepsis, to septic shock, to multiple organ failure. When SIRS is the result of a confirmed
infectious process, it is termed sepsis. Sepsis is defined as a systemic response to
infection by microbes or their products.
Product
Segments
Scores of agents have been suggested for possible prevention or treatment of sepsis.
Many are untested, a few have been tried clinically, and a few have been tried clinically
and failed.
Market Share
If Xoma/Pfizer's E5 (edobacomab), a murine monoclonal antibody antisepsis product,
enters the U.S. market in 1998 as projected, it would be the greatest contributor to the
sepsis product market, which in that year could reach $300 million.
Costs
It is estimated that the cost of treating sepsis and septic shock averages $16,000 per
patient in the United States. Hospital charges range from $5 billion to $10 billion
annually.
Issues and
Trends
Resistance to available anti-infectives is increasing at an alarming rate. Overuse and
careless use of anti-infectives have resulted in a situation in which resistance is
increasing more rapidly than efforts to contain it.
The Patient
In 1992, 637,597 people in the United States were hospitalized with sepsis. This
represents a 7% increase from 1991, when 596,213 patients were diagnosed with the
disease. Approximately 45% of patients with sepsis progress to septic shock, and
approximately 100,000 Americans die from septic shock annually.
Industry
Structure
Less than 20 companies in 1995 state that they are actively pursuing the development of
drugs to prevent or treat sepsis or septic shock. Given the unpopularity of the word
"sepsis" on Wall Street, it is believed that many more companies are working on
compounds that could be used for this indication, but are being developed for others.
Company
Profiles
Alpha-Beta Technology, Inc.
Biogen, Inc.
Genentech, Inc.
Immunex Corp.
T Cell Sciences, Inc.
Xoma Corp.
Go Home | Search | Request Research | Clients Only | Send Message | Keep Me Posted
|
